Hypogonadism Therapeutic Risks, Benefits, and Outcomes

作者：Sigalos John T; Pastuszak Alexander W; Khera Mohit^*

来源：Medical Clinics of North America, 2018, 102(2): 361-+.

DOI：10.1016/j.mcna.2017.10.011

• Hypogonadism
• Cardiovascular risk
• Testosterone therapy
• Outcomes

Hypogonadism is a common condition defined by the presence of low serum testosterone levels and hypogonadal symptoms and most commonly treated using testosterone therapy (TTh). The accuracy of diagnosis and appropriateness of treatment, along with proper follow-up, are increasingly important given the large increase in testosterone prescriptions and the recent concern for cardiovascular (CV) risk associated with TTh. In March of 2015, the US Food and Drug Administration required that testosterone product labels disclose a potential CV risk, despite the evidence base for this association being weak and inconclusive. However, TTh may improve CV outcomes rather than increase risks.

• 出版日期2018-3